A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis

@inproceedings{Mcauliffe2008ARP,
  title={A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis},
  author={John C Mcauliffe and Kelly K. Hunt and Alexander J Lazar and Haesun Choi and Wei Qiao and Peter F. Thall and Raphael E Pollock and Robert S Benjamin and Jonathan C. Trent},
  booktitle={Annals of Surgical Oncology},
  year={2008}
}
Gastrointestinal stromal tumor (GIST) is the most common sarcoma arising in the gastrointestinal (GI) tract. Imatinib mesylate (imatinib) is efficacious in treating advanced and metastatic GIST. Patients undergoing resection of GIST realize a highly variable median disease-free survival (DFS). In the absence of prospective data, we conducted a randomized, phase II study to assess the safety and efficacy of preoperative and postoperative imatinib for the treatment of GIST. Nineteen GIST patients… CONTINUE READING